Items where authors include "Faivre-Finn, C."

Article

Wheelwright, S., Minton, O., Absolom, K. orcid.org/0000-0002-5477-6643 et al. (10 more authors) (2025) Integrating ePROMs: A key opportunity for England’s National Cancer Plan. Journal of Cancer Policy, 44. 100575. ISSN 2213-5383

Fornacon-Wood, I., Nuamek, T., Hudson, E.M. et al. (9 more authors) (2024) Analyzing patient-reported outcome data in oncology care. International Journal of Radiation Oncology • Biology • Physics. ISSN 0360-3016

Liao, K., Wong, D.C. orcid.org/0000-0001-8117-9193, Gomes, F. et al. (5 more authors) (2024) Exploring the value of routinely collected data on EQ-5D-5L and other electronic patient-reported outcome measures as prognostic factors in adults with advanced non-small cell lung cancer receiving immunotherapy. BMJ Oncology, 3 (1). e000158. ISSN 2752-7948

Kapadi, A., Price, G., Faivre-Finn, C. et al. (8 more authors) (2024) Feasibility of implementing a rapid-learning methodology to inform radiotherapy treatments: key professional stakeholders’ views. BMJ Oncology, 3 (1). e000226. ISSN 2752-7948

Spencer, K.L. orcid.org/0000-0002-6846-4341, Absolom, K.L., Allsop, M.J. et al. (11 more authors) (2023) Fixing the Leaky Pipe: How to Improve the Uptake of Patient-Reported Outcomes–Based Prognostic and Predictive Models in Cancer Clinical Practice. JCO Clinical Cancer Informatics, 7. e2300070. ISSN 2473-4276

Fornacon-Wood, I., Banfill, K., Ahmad, S. et al. (22 more authors) (2023) Impact of the COVID-19 pandemic on outcomes for patients with lung cancer receiving curative-intent radiotherapy in the UK. Clinical Oncology, 35 (10). e593-e600. ISSN 0936-6555

Walker, K. orcid.org/0000-0001-6922-9100, Hinsley, S., Phillip, R. orcid.org/0000-0002-9604-9276 et al. (6 more authors) (2022) Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations—CONCORDE. JCO Precision Oncology, 6 (6). e2200133. ISSN 2473-4284

Horne, A., Brown, S., Butterworth, K. et al. (26 more authors) (2022) EP05.01-007 CONCORDE - A Phase Ib Platform Study of Novel Agents in COmbinatioN with COnventional RaDiothErapy in Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 17 (9). s267-s268. ISSN 1556-0864

Vasey, B., Nagendran, M., Campbell, B. et al. (152 more authors) (2022) Reporting guideline for the early stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI. British Medical Journal (The BMJ), 377. e070904. ISSN 1759-2151

Banfill, K., Croxford, W., Fornacon-Wood, I. et al. (22 more authors) (2022) Changes in the management of patients having radical radiotherapy for lung cancer during the first wave of the COVID-19 pandemic in the UK. Clinical Oncology, 34 (1). pp. 19-27. ISSN 0936-6555

Le Pechoux, C., Pourel, N., Barlesi, F. et al. (25 more authors) (2022) Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-label, randomised, phase 3 trial. The Lancet Oncology, 23 (1). pp. 104-114. ISSN 1470-2045

Punjabi, A., Barrett, E., Cheng, A. et al. (21 more authors) (2021) Neutrophil–lymphocyte ratio and absolute lymphocyte count as prognostic markers in patients treated with curative-intent radiotherapy for non-small cell lung cancer. Clinical Oncology, 33 (8). e331-e338. ISSN 0936-6555

Haslett, K., Bayman, N., Franks, K. et al. (10 more authors) (2021) Isotoxic intensity modulated radiation therapy in stage III non-small cell lung cancer: a feasibility study. International Journal of Radiation Oncology*Biology*Physics, 109 (5). pp. 1341-1348. ISSN 0360-3016

Evison, M., Barrett, E., Cheng, A. et al. (20 more authors) (2021) Predicting the risk of disease recurrence and death following curative-intent radiotherapy for non-small cell lung cancer: The development and validation of two scoring systems from a large multicentre UK cohort. Clinical Oncology, 33 (3). pp. 145-154. ISSN 0936-6555

Faivre-Finn, C., Fenwick, J.D., Franks, K.N. et al. (11 more authors) (2020) Reduced fractionation in lung cancer patients treated with curative-intent radiotherapy during the COVID-19 pandemic. Clinical Oncology, 32 (8). pp. 481-489. ISSN 0936-6555

Mcdonald, F., Senan, S., Faivre-Finn, C. et al. (1 more author) (2019) Curative radiotherapy for non-small cell lung cancer : practice changing and changing practice? Clinical Oncology, 31 (10). pp. 678-680. ISSN 0936-6555

Woolhouse, I., Bishop, L., Darlison, L. et al. (14 more authors) (2019) BTS guideline for the investigation and management of malignant pleural mesothelioma. BMJ Open Respiratory Research, 5 (1). e000266. ISSN 2052-4439

Bayman, N., Appel, W., Ashcroft, L. et al. (16 more authors) (2019) Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma : an open-label, multicenter, phase III randomized trial. Journal of Clinical Oncology, 37 (14). pp. 1200-1208. ISSN 0732-183X

Salem, A., Mistry, H., Hatton, M. et al. (4 more authors) (2019) Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial. JAMA Oncology, 5 (3). e185335. ISSN 2374-2437

Woolhouse, I., Bishop, L., Darlison, L. et al. (14 more authors) (2018) British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. Thorax, 73 (Suppl 1). i1-i30. ISSN 0040-6376

Faivre-Finn, C., Snee, M., Ashcroft, L. et al. (17 more authors) (2017) Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. The Lancet Oncology, 18 (8). pp. 1116-1125. ISSN 1470-2045

Slotman, B.J., Faivre-Finn, C., van Tinteren, H. et al. (12 more authors) (2017) Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial. Lung Cancer, 108. pp. 150-153. ISSN 0169-5002

O'Connor, J.P.B., Aboagye, E.O., Adams, J.E. et al. (74 more authors) (2017) Imaging biomarker roadmap for cancer studies. Nature Reviews Clinical Oncology, 14. pp. 169-186. ISSN 1759-4774

Mulvenna, P., Nankivell, M., Barton, R. et al. (16 more authors) (2016) Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. The Lancet, 388 (10055). pp. 2004-2014. ISSN 0140-6736

Haslett, K., Franks, K., Hanna, G.G. et al. (12 more authors) (2016) Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study. BMJ Open, 6 (4). e010457. e010457-e010457. ISSN 2044-6055

Bayman, N., Ardron, D., Ashcroft, L. et al. (12 more authors) (2016) Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention. BMJ Open, 6 (1). ARTN e010589. e010589-e010589. ISSN 2044-6055

Conference or Workshop Item

Horne, A., Ali, A., Brown, S. et al. (28 more authors) (2022) 153 CONCORDE: a phase Ib platform study of novel agents in combination with conventional radiotherapy in non-small cell lung cancer (NSCLC). In: 20th Annual British Thoracic Oncology Group Conference 2022, 27-28 Jan 2022, Virtual.

Proceedings Paper

Greystoke, A., Oughton, J.B., Brown, S.R. et al. (16 more authors) (2024) Olaparib, AZD1390, ceralasertib, saruparib and consolidation durvalumab (CONCORDE) phase Ib platform study of novel DNA damage response inhibitor (DDRi) agents in combination with radiotherapy in non-small cell lung cancer (NSCLC). In: Journal of Clinical Oncology. 2024 ASCO Annual Meeting, 31 May - 04 Jun 2024, Chicago, USA. ASCO Publications .

Horne, A., Brown, S., Coyle, V. et al. (13 more authors) (2023) P2.01-04 An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC. In: Journal of Thoracic Oncology. 2023 World Conference on Lung Cancer, 09-12 Sep 2023, Singapore. Elsevier BV , S296-S297.

Horne, A., Brown, S., Coyle, V. et al. (13 more authors) (2023) An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC. In: Journal of Thoracic Oncology. 2023 World Conference on Lung Cancer, 09-12 Sep 2023, Singapore. Elsevier , S296-S297.

Simoes, R., Patel, E., Groom, N. et al. (8 more authors) (2018) PO-1068: ADSCAN: Feasibility of implementing adequate technology for a 'pick the winner' trial in lung cancer. In: Radiotherapy and Oncology. ESTRO 37, 20-24 Apr 2018, Barcelona, Spain. , S599-S600.

Bayman, N., Appel, W., Ashcroft, L. et al. (15 more authors) (2018) OC-0537: Prophylactic irradiation of tracts (PIT) in patients with pleural mesothelioma: a phase III trial. In: Radiotherapy and Oncology. ESTRO 37, 20-24 Apr 2018, Barcelona, Spain. Elsevier , S286-S287.

Haslett, K., Ashcroft, L., Bayman, N. et al. (11 more authors) (2018) PO-0752: Isotoxic Intensity Modulated Radiotherapy in stage III NSCLC – A feasibility study. In: Radiotherapy and Oncology. ESTRO 37, 20-24 Apr 2018, Barcelona, Spain. Elsevier , S387-S387.

Lawless, C., Boyd, K., Faivre-Finn, C. et al. (9 more authors) (2018) ADSCaN: a randomised phase ii study of accelerated, dose escalated, sequential chemo-radiotherapy in non-small cell lung cancer (NSCLC). In: Lung Cancer. The 16th Annual British Thoracic Oncology Group Conference 2018, 24-26 Jan 2018, Dublin . Elsevier , S88-S89.

Bayman, N., Appel, W., Ashcroft, L. et al. (14 more authors) (2018) Prophylactic irradiation of tracts (PIT) in patients with pleural mesothelioma: results of a multicentre phase III trial. In: Lung Cancer. 16th Annual British Thoracic Oncology Group Conference 2018, 24-26 Jan 2018, Dublin, Ireland. Elsevier , S30-S30.

Haslett, K., Bayman, N., Franks, K. et al. (11 more authors) (2017) MA 09.11 Isotoxic Intensity Modulated Radiotherapy (IMRT) in Stage III Non-Small Cell Lung Cancer (NSCLC) – a feasibility study. In: Journal of Thoracic Oncology. IASLC 18th World Conference on Lung Cancer, 15-18 Oct 2017, Yokohama, Japan. Elsevier , S1838-S1839.

Hanna, G., McDonald, F., Greystoke, A. et al. (7 more authors) (2017) EP-1228 : UK NCRI CTRad consensus on drug and radiotherapy combination platform studies in NSCLC. In: Radiotherapy and Oncology. ESTRO 36 - European Society for Radiotherapy & Oncology, 05-09 May 2017, Vienna, Austria. Elsevier , S662-S663.

Preprint

Perry, M.B. orcid.org/0009-0002-2978-2272, Taylor, S., Khatoon, B. et al. (6 more authors) (2023) Effectiveness of electronic patient-reported outcomes in people with cancer: a systematic review and meta-analysis. [Preprint]